Seelos Therapeutics Faces Liquidation Following Court-Approved Asset Sale

A New York bankruptcy judge has authorized the sale of Seelos Therapeutics’ remaining assets for $22 million, effectively concluding the biotechnology firm’s protracted financial collapse. The September 17 ruling approved a credit bid from GLD Debt Acquisition, which had previously acquired the company’s secured debt obligations.

Contentious Liquidation Process

The asset disposal faced significant opposition from unsecured creditors’ committees, requiring additional concessions to proceed. Objections were ultimately resolved through a $100,000 cash payment plus $25,000 allocated for contractual expenses. Certain assets were excluded from the primary sale and are scheduled for separate auctions, with anticipated proceeds between $175,000 and $200,000. These amounts represent minimal recovery compared to outstanding liabilities.

Regulatory Demotion and Trading Restrictions

The company’s decline accelerated in October 2024 when Nasdaq delisted Seelos shares for failure to meet minimum equity requirements. Since October 16, 2024, trading has been relegated to the OTCQB market, with subsequent demotion to the Expert Market under the ticker SEELQ.

This regulatory status carries substantial consequences for shareholders:
* Expert Market Classification: Designated “Unsolicited Quotes Only” with explicit extreme risk warnings
* Trading Challenges: Dramatically widened bid-ask spreads and elevated transaction costs
* Limited Liquidity: Severely constrained trading volume with minimal price discovery

Should investors sell immediately? Or is it worth buying Seelos Therapeutics?

Failed Financial Engineering

Management attempted multiple interventions to avert collapse, implementing two reverse stock splits within months:
* 1:8 ratio consolidation in May 2024
* 1:16 ratio consolidation in September 2024

These maneuvers failed to address fundamental financial deficiencies or create sustainable market confidence. The company filed for Chapter 11 bankruptcy protection in November 2024, culminating in the recent asset sale approval.

Recent trading data from October 3, 2025, confirms the equity’s diminished status, with minimal volume transacting at fractional prices. The former Nasdaq-listed biotech security now exists primarily as a speculative instrument for risk-tolerant traders, though actual trading activity remains exceptionally limited.